A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma

Status Completed

Clinical Trial Summary

This clinical study is looking at a vaccine called MVA-EBNA1/LMP2. This is a new vaccine that has already been studied in small number of cancer patients.

The vaccine is designed to boost a patient's immunity against a common virus. The virus is called Epstein Barr virus or EBV. EBV is sometimes found inside cancer cells and is commonly found in nasopharyngeal cancer cells.

Clinical Trial Description

The main aims of the clinical study are to find out more about how the immune system responds to the vaccine, more about the potential side effects of the vaccine and the effects of giving an additional booster vaccination on the immune system.

Approximately 18 patients with EBV positive nasopharyngeal cancer (NPC) will be recruited to the trial. Patients will receive up to four vaccinations with the MVA-EBNA1/LMP2 vaccine. The first three vaccines will be given at 3 weekly intervals, followed by a fourth vaccine 12 weeks later. The vaccine will be given by intradermal injection with the dose divided across multiple injection sites on the arm, or on the thigh.

Patients will participate in the study for approximately 12 months from first vaccination and attend hospital approximately 11 times during this period. Standard safety assessments will be performed throughout the trial and at each clinic visit patients will be asked to provide research blood samples. These samples will be used to monitor the effects of the vaccine on the patient's immune system. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01800071
Study type	Interventional
Source	Cancer Research UK
Contact
Status	Completed
Phase	Phase 1
Start date	March 2013
Completion date	March 10, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00370890` - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy	Phase 3
Recruiting	`NCT04340024` - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Completed	`NCT00697619` - To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer	Phase 2
Completed	`NCT00078546` - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)	Phase 1
Recruiting	`NCT04453826` - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Phase 3
Active, not recruiting	`NCT01074021` - Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer	Phase 3
Active, not recruiting	`NCT03890185` - Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC	Phase 2
Not yet recruiting	`NCT04158414` - Applying PET/MR in Oncology - a Prospective Project	N/A
Completed	`NCT02608073` - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer	Phase 2
Completed	`NCT03656250` - Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT04476641` - A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors	Phase 2
Terminated	`NCT03144661` - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies	Phase 1
Recruiting	`NCT03003182` - A Study of Nasopharyngeal Carcinoma From Guangdong	N/A
Not yet recruiting	`NCT06349889` - Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma	Phase 2
Completed	`NCT01094405` - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy	Phase 2
Not yet recruiting	`NCT05305131` - Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer	Phase 2
Recruiting	`NCT00304694` - Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients	N/A
Recruiting	`NCT05638269` - A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
Not yet recruiting	`NCT04875611` - Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment	Phase 2